Efficacy and safety of tixagevimab-cilgavimab (Evusheld®) in people with Multiple Sclerosis on Ocrelizumab: preliminary evidence-Reference-Cited by-同舟云学术

Efficacy and safety of tixagevimab-cilgavimab (Evusheld®) in people with Multiple Sclerosis on Ocrelizumab: preliminary evidence

Published:2023-07-27 Issue:11 Volume:44 Page:4107-4110
ISSN:1590-1874
Container-title:Neurological Sciences
language:en
Short-container-title:Neurol Sci

Author:

Altieri Manuela,Melisi Rosario Domenico,Conte Miriana,Capuano Rocco,Donnarumma Giovanna,Grimaldi Elena,Coppola Nicola,De Pascalis Stefania,Risi Mario,d’Ambrosio Alessandro,Bisecco Alvino,Gallo Antonio^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Neurology (clinical),Dermatology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10072-023-06975-7.pdf

Reference14 articles.

1. Sormani MP, Inglese M, Schiavetti I et al (2021) Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine 72:103581. https://doi.org/10.1016/j.ebiom.2021.103581

2. Italian Medicines Agency (2022) Attivazione web e pubblicazione schede di monitoraggio - Registro EVUSHELD profilassi COVID-19. https://www.aifa.gov.it/en/-/attivazione-web-e-pubblicazione-schede-di-monitoraggio-registro-evusheld-profilassi-covid-19. Accessed 6 Jul 2023

3. Gelfand JM, Cree BAC, Hauser SL (2017) Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis. Neurotherapeutics 14:835–841. https://doi.org/10.1007/s13311-017-0557-4

4. Gallo A, Capuano R, Donnarumma G et al (2021) Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab. Neurol Sci 42:3523–3526. https://doi.org/10.1007/s10072-021-05397-7

5. Capuano R, Bisecco A, Conte M, et al (2022) Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod. Mult Scler Relat Disord 60:103724 https://doi.org/10.1016/j.msard.2022.103724

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tixagevimab/Cilgavimab does not prevent COVID-19 in patients with multiple sclerosis and related disorders on B-cell depleting therapies;Multiple Sclerosis and Related Disorders;2024-07